CD20/MS4A1 Recombinant Proteins and Antibodies

CD20, encoded by the MS4A1 gene, is a non-secreted, non-internalizing transmembrane protein that is stably expressed from the pre-B cell to mature B cell stages, but absent in stem cells and plasma cells. Due to its well-defined localization during B cell development, stable expression, and strong association with both B-cell malignancies and autoimmune diseases, CD20 has become a major target in therapeutic antibody development. Functionally, it is involved in calcium channel regulation and B cell activation, but it is not essential for normal physiology. Therefore, antibody-mediated depletion of CD20⁺ B cells can effectively modulate pathological immune responses with minimal impact on overall immune function.

In drug development, Rituximab was the first monoclonal antibody against CD20 approved for clinical use. It revolutionized B cell–depletion therapy and has been widely used in treating non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Subsequently, second- and third-generation CD20 antibodies such as Ofatumumab and Obinutuzumab were developed, showing improvements in affinity, cytotoxic mechanisms (CDC/ADCC), and safety profiles. In parallel, CD20-targeted bispecific antibodies and CAR-T cell therapies are under active investigation to enhance efficacy and overcome drug resistance. CD20-targeting agents have now become therapeutic mainstays in hematologic malignancies and autoimmune diseases, with a continuously expanding global market. Future research focuses on improving antibody potency, reducing immune-related adverse effects, and exploring combination therapies across broader indications. With the advancement of next-generation immunotherapies, CD20 is expected to continue playing a central role in precision medicine and immune-oncology. Learn more about CD20 drug research >>

DIMA BIOTECH provides a comprehensive range of ready-to-use CD20-related products, including recombinant proteins, full-length membrane proteins, recombinant monoclonal antibodies, biotin/PE-labeled antibodies, and stable cell lines. We also offer systematic services such as custom protein/antibody development, antibody humanization, affinity maturation, and stable cell line construction. In addition, we have established a B-cell seed library targeting CD20, enabling the rapid screening and identification of desired lead antibody molecules within 20 days. For more information, please feel free to contact us.